Advanced search×

Annual General Meeting of the ICS, 7–9 Oct 2010

Author(s) unavailable

Ir J Med Sci 179(S10):375-412 (2010) PMID 20821274

DOI: 10.1007/s11845-010-0539-6
Version: za2963e q8za9 q8zba q8zc1 q8zd8 q8zee q8zf7 q8zg3

Similar articles you may find interesting…

  1. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, ...
    Robert L RL Hudkins, Rita R Raddatz, ... Michael M Williams

    J Med Chem 54(13):4781-92 (2011) PMID 21634396

    Optimization of a novel series of pyridazin-3-one histamine H(3) receptor (H(3)R) antagonists/inverse agonists identified 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (8a, CEP-26401; irdabisant) as a lead candidate for potential use in the treatment of atten...
  2. Salt, aldosterone, and insulin resistance: impact on the cardiovascular system.
    Guido Lastra, Sonal Dhuper, ... James R Sowers

    Nat Rev Cardiol 7(10):577-84 (2010) PMID 20697411

    Hypertension and type 2 diabetes mellitus (T2DM) are powerful risk factors for cardiovascular disease (CVD) and chronic kidney disease (CKD), both of which are leading causes of morbidity and mortality worldwide. Research into the pathophysiology of CVD and CKD risk factors has ident...
  3. Novel therapeutic targets for hypertension.
    Ludovit L Paulis and Thomas T Unger

    Nat Rev Cardiol 7(8):431-41 (2010) PMID 20567239